| AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis DA Kircher, KA Trombetti, MR Silvis, GL Parkman, GM Fischer, SN Angel, ... Molecular Cancer Research 17 (9), 1787-1800, 2019 | 64 | 2019 |
| Nanoscale imaging of collagen gels with focused ion beam milling and scanning electron microscopy SP Reese, N Farhang, R Poulson, G Parkman, JA Weiss Biophysical journal 111 (8), 1797-1804, 2016 | 31 | 2016 |
| Interaction of the Jhd2 histone H3 Lys-4 demethylase with chromatin is controlled by histone H2A surfaces and restricted by H2B ubiquitination F Huang, S Ramakrishnan, S Pokhrel, C Pflueger, TJ Parnell, MM Kasten, ... Journal of Biological Chemistry 290 (48), 28760-28777, 2015 | 23 | 2015 |
| Inhibition of MEK1/2 forestalls the onset of acquired resistance to entrectinib in multiple models of NTRK1-driven cancer A Vaishnavi, MT Scherzer, CG Kinsey, GL Parkman, A Truong, P Ghazi, ... Cell reports 32 (5), 2020 | 22 | 2020 |
| The role of PI3'‐lipid signalling in melanoma initiation, progression and maintenance GL Parkman, M Foth, DA Kircher, SL Holmen, M McMahon Experimental dermatology 31 (1), 43-56, 2022 | 11 | 2022 |
| Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy WJ Burnett, DM Burnett, G Parkman, A Ramstead, N Contreras, W Gravley, ... Cancers 13 (17), 4462, 2021 | 6 | 2021 |
| Genetic silencing of AKT induces melanoma cell death via mTOR suppression GL Parkman, T Turapov, DA Kircher, WJ Burnett, CM Stehn, K O'Toole, ... Molecular Cancer Therapeutics 23 (3), 301-315, 2024 | 3 | 2024 |
| RAC1mutation is not a predictive biomarker for PI3’‐kinase‐β‐selective pathway‐targeted therapy M Foth, G Parkman, B Battistone, M McMahon Pigment Cell & Melanoma Research 33 (5), 719-730, 2020 | 3 | 2020 |
| Genetic silencing of AKT induces melanoma cell death GL Parkman, T Turapov, DA Kircher, WJ Burnett, CM Stehn, K O’Toole, ... Biorxiv, 2022.08. 15.504039, 2022 | 1 | 2022 |
| Combined inhibition of RAF, MEK, and FAK attenuates melanoma brain metastases and prolongs survival in preclinical models KA Stanley, JD Almazan, T Turapov, DA Kircher, GL Parkman, MKN Field, ... Cancer Research 84 (6_Supplement), 4127-4127, 2024 | | 2024 |
| A Paradoxical AKT: Exploring the Promise and Challenges of PI3K/AKT/mTOR Targeted Therapies GL Parkman, SL Holmen Journal of cancer immunology 6 (3), 92, 2024 | | 2024 |
| Human Rhinoviruses: a novel class of oncolytic virus WJ Burnett, A Cluff, M Reeves, GL Parkman, C Hart, A Ramstead, ... bioRxiv, 2023.05. 31.542867, 2023 | | 2023 |
| Newer generation mTOR inhibition represents effective therapeutic strategy for BRAF-mutant melanoma GL Parkman, T Turapov, D Kircher, W Burnett, C Stehn, K O'Toole, ... Cancer Research 83 (7_Supplement), 427-427, 2023 | | 2023 |
| Model-dependent outcomes: Sex as a biological variable in preclinical mouse models of melanoma GL Parkman, DA Kircher, CM Stehn, M McMahon, SL Holmen Pigment cell & melanoma research, 10.1111/pcmr. 12940, 2020 | | 2020 |
| Elucidating the role of PI3K lipid effectors in BRAF mutant melanoma G Parkman, J Cho, S Holmen, M McMahon Cancer Research 80 (16_Supplement), 1616-1616, 2020 | | 2020 |
| AKT1E17K activates focal adhesion kinase and promotes melanoma brain metastasis DA Kircher, KA Trombetti, MR Silvis, GL Parkman, GM Fischer, SN Angel, ... Cancer Research 80 (16_Supplement), 2736-2736, 2020 | | 2020 |
